Foster Communications and Cello Health join forces to launch sustainability service
Forster Communications and Cello Health have collaborated to offer the pharma industry a new sustainability service.
The recently launched ‘Sustainable Pharma Futures’ is a programme that will help shape sustainability policies within companies.
Enhancing company reputation, driving innovation culture and productivity support are among the programme’s objectives and are areas that are often “siloed internally and hidden from view”, says Forster Communications’ CEO Amanda Powell-Smith.
She said these areas are often “not joined up or realising its full value in driving positive change for the business, its stakeholders and society. We believe that the majority of pharmaceutical businesses are sitting on untapped potential and want to make sustainability good for society and good for business”.
According to a report by the Business and Sustainable Development Commission, achieving sustainable businesses could unlock a global market worth $12 trillion and $1.8 trillion of that accounts for health and wellbeing.
Although, business sustainability is not connected to work happening across the organisation such as employee wellbeing, product development and facilities management, says the companies.
Through utilising communications, the new initiative aims to bring all of those areas together and identify opportunities that can be strengthened.
Cello will bring its experience of the pharma industry to the collaboration while Forster will offer its expertise in social change communications.
Cello Health Communications Corporate Affairs Head, Jo Taylor adds: “The market is changing – from commissioner buying habits to the fight for talent – and we have created Sustainable Pharma Futures to help organisations respond to this. The combined skills and experience of our two organisations give corporate affairs directors instant access to knowledge and insights on how they can build their role as ethical, responsible organisations who are making a difference. This is no longer a nice-to-do, it’s about securing a future for pharmaceutical businesses to operate in.”